Richard Bryce

5.8k total citations
54 papers, 1.3k citations indexed

About

Richard Bryce is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Richard Bryce has authored 54 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Richard Bryce's work include HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (12 papers) and Cancer Treatment and Pharmacology (10 papers). Richard Bryce is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (12 papers) and Cancer Treatment and Pharmacology (10 papers). Richard Bryce collaborates with scholars based in United States, United Kingdom and Spain. Richard Bryce's co-authors include Wen G. Jiang, David F. Horrobin, Robert E. Mansel, Gareth M. Watkins, Robert E. Mansel, Anthony Douglas-Jones, Sung‐Bae Kim, Stephen Hiscox, F.S. Kenny and Andrew Redfern and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Richard Bryce

50 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Bryce United States	19	636	450	361	265	172	54	1.3k
Christopher A. Carter United States	12	804 1.3×	948 2.1×	497 1.4×	502 1.9×	221 1.3×	15	2.4k
Yukio Morishita Japan	23	628 1.0×	768 1.7×	343 1.0×	243 0.9×	73 0.4×	97	2.0k
Mi Ran Yun South Korea	22	558 0.9×	622 1.4×	483 1.3×	268 1.0×	42 0.2×	49	1.4k
Paula Sotomayor United States	22	298 0.5×	658 1.5×	307 0.9×	246 0.9×	111 0.6×	32	1.3k
Quintin Pan United States	20	739 1.2×	756 1.7×	261 0.7×	370 1.4×	436 2.5×	40	1.8k
Senthil Pazhanisamy United States	11	333 0.5×	665 1.5×	168 0.5×	256 1.0×	37 0.2×	12	1.3k
Jianqing Lin United States	22	491 0.8×	849 1.9×	515 1.4×	312 1.2×	51 0.3×	62	1.7k
D L Baly United States	15	1.2k 1.8×	720 1.6×	171 0.5×	246 0.9×	176 1.0×	20	2.0k
Uma Giri United States	23	472 0.7×	984 2.2×	263 0.7×	489 1.8×	41 0.2×	51	1.6k
Mingxin Che United States	25	582 0.9×	703 1.6×	457 1.3×	440 1.7×	56 0.3×	36	1.9k

Countries citing papers authored by Richard Bryce

Since Specialization

Citations

This map shows the geographic impact of Richard Bryce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Bryce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Bryce more than expected).

Fields of papers citing papers by Richard Bryce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Bryce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Bryce. The network helps show where Richard Bryce may publish in the future.

Co-authorship network of co-authors of Richard Bryce

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Bryce. A scholar is included among the top collaborators of Richard Bryce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Bryce. Richard Bryce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joshi, Shreyas, Matthew Bui, Rian J. Dickstein, et al.. (2024). P2-08 LEGEND: A PHASE 1/2 STUDY OF EG-70 (DETALIMOGENE VORAPLASMID), A NOVEL, NON-VIRAL INTRAVESICAL GENE THERAPY FOR PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU (CIS). The Journal of Urology. 211(5S2). 3 indexed citations

Bryce, Richard, et al.. (2024). A phase 1/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.. Journal of Clinical Oncology. 42(16_suppl). TPS4626–TPS4626. 2 indexed citations

Goulet, Marie-Line, Shauna Dauphinee, Kristine S. Louis, et al.. (2024). Abstract PR006: EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: Preclinical characterization and translation into the clinic. Clinical Cancer Research. 30(10_Supplement). PR006–PR006. 1 indexed citations

Jones, Robin L., Roberta Sanfilippo, Scott M. Schuetze, et al.. (2023). LBA89 Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas. Annals of Oncology. 34. S1331–S1331. 5 indexed citations

Sanfilippo, Roberta, Robin L. Jones, Scott M. Schuetze, et al.. (2023). 76MO Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas. Annals of Oncology. 34. S1496–S1496. 4 indexed citations

Saura, Cristina, Judit Matito, Mafalda Oliveira, et al.. (2021). Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 27(21). 5818–5827. 15 indexed citations

Iwata, Hiroji, Norikazu Masuda, Sung‐Bae Kim, et al.. (2019). Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients from Asia with Early Stage HER2-Positive Breast Cancer. Future Oncology. 15(21). 2489–2501. 7 indexed citations

Xu, Binghe, Sung‐Bae Kim, Kenichi Inoue, et al.. (2019). Neratinib-Based Therapy in Patients with Metastatic HER2-Positive Breast Cancer from Asia. Future Oncology. 15(28). 3243–3253. 3 indexed citations

Rugo, Hope S., Jack A. Di Palma, Debu Tripathy, et al.. (2019). The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Research and Treatment. 175(1). 5–15. 50 indexed citations

10.

Sudhan, Dhivya R., Luis J. Schwarz, Ángel Guerrero‐Zotano, et al.. (2018). Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clinical Cancer Research. 25(2). 771–783. 26 indexed citations

11.

Saura, Cristina, et al.. (2015). Effective Management and Prevention of Neratinib-Induced Diarrhea. 11(11). 16 indexed citations

12.

Hájek, Roman, Richard Bryce, Sunhee Ro, Barbara Klencke, & Heinz Ludwig. (2012). Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 12(1). 415–415. 43 indexed citations

13.

Watkins, Gareth M., Tracey A. Martin, Richard Bryce, Robert E. Mansel, & Wen G. Jiang. (2005). γ-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells. Prostaglandins Leukotrienes and Essential Fatty Acids. 72(4). 273–278. 19 indexed citations

14.

Kenny, F.S., Julia M.W. Gee, Robert I. Nicholson, et al.. (2001). Effect of dietary GLA+/?tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts. International Journal of Cancer. 92(3). 342–347. 19 indexed citations

15.

Abulrob, Abedelnasser, Malcolm Mason, Richard Bryce, & Mark Gumbleton. (2000). The Effect of Fatty Acids and Analogues upon Intracellular Levels of Doxorubicin in Cells Displaying P-Glycoprotein Mediated Multidrug Resistance. Journal of drug targeting. 8(4). 247–256. 25 indexed citations

16.

Jiang, Wen G., Andrew Redfern, Richard Bryce, & Robert E. Mansel. (2000). Peroxisome proliferator activated receptor-γ (PPAR-γ) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukotrienes and Essential Fatty Acids. 62(2). 119–127. 60 indexed citations

17.

Jiang, Wen G., Stephen Hiscox, Richard Bryce, David F. Horrobin, & R E Mansel. (1998). The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. British Journal of Cancer. 77(5). 731–738. 32 indexed citations

18.

Jiang, Wen G., Stephen Hiscox, David F. Horrobin, Richard Bryce, & Robert E. Mansel. (1997). Gamma Linolenic Acid Regulates Expression of Maspin and the Motility of Cancer Cells. Biochemical and Biophysical Research Communications. 237(3). 639–644. 35 indexed citations

19.

Jiang, Wen G., Sim K. Singhrao, Stephen Hiscox, et al.. (1997). Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids. Clinical & Experimental Metastasis. 15(6). 593–602. 18 indexed citations

20.

Jiang, Wen G., Richard Bryce, & Robert E. Mansel. (1997). Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells. Prostaglandins Leukotrienes and Essential Fatty Acids. 56(4). 307–316. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact